Nilotinib Lauryl Sulfate (Handa Oncology)

N/A

Report date: 2025/02/07 16:09:58

Base Information

Drug NameNilotinib Lauryl Sulfate (Handa Oncology)
Drug Alias NameNilotinib ONCORENilotinib Laurylsulfate
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsStem cell growth factor receptorBcr-Abl tyrosine kinasePlatelet-derived growth factor receptor +[4] 
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHanda Oncology LLC
China Registration ClassN/A

Develop Information

Active CompaniesHanda Oncology LLC
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A